The FDA has approved the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
Read more: FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer